, Corrélation entre la progression confirmée iRECIST et l'absence de bénéfice clinique prolongé
Patients de statut intermédiaire (progression non confirmée et stabilité), p.38 ,
,
,
, Corrélation entre la progression confirmée iPERCIST et l'absence de bénéfice clinique prolongé
Patients de statut intermédiaire (progression non confirmée et stabilité), p.41 ,
,
,
45 2. Corrélation entre la progression confirmée et l'absence de bénéfice clinique prolongé ,
48 3. Corrélation entre la progression et l'absence de bénéfice clinique prolongé ,
,
,
Cancer Incidence and Mortality Worldwide: Sources, Methods and Major Patterns in GLOBOCAN 2012, International Journal of Cancer, vol.136, issue.5, pp.359-386, 2015. ,
A Changing of the Guard: Immune Checkpoint Inhibitors With and Without Chemotherapy as First Line Treatment for Metastatic Non-Small Cell Lung Cancer, Frontiers in Oncology, vol.9, 2019. ,
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer, The New England Journal of Medicine, vol.372, issue.21, pp.2018-2046, 2015. ,
,
Activity and Safety of Nivolumab, an Anti-PD-1 Immune Checkpoint Inhibitor, for Patients with Advanced, Refractory Squamous Non-Small-Cell Lung Cancer (CheckMate 063): A Phase 2, Single-Arm Trial, The Lancet. Oncology, vol.16, issue.3, p.257, 2015. ,
Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, 2018. ,
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer, The New England Journal of Medicine, vol.373, issue.2, pp.123-158, 2015. ,
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer, The New England Journal of Medicine, vol.375, issue.19, pp.1823-1856, 2016. ,
Nivolumab versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer, The New England Journal of Medicine, vol.373, issue.17, pp.1627-1666, 2015. ,
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome, Frontiers in Pharmacology, vol.8, 2017. ,
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations, Frontiers in Oncology, vol.8, 2018. ,
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck, The New England Journal of Medicine, vol.375, issue.19, pp.1856-67, 2016. ,
Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma, The New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015. ,
,
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer, The New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012. ,
New Response Evaluation Criteria in Solid Tumours: Revised RECIST Guideline (Version 1.1), European Journal of Cancer, vol.45, issue.2, pp.228-275, 1990. ,
,
Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer, Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, vol.13, issue.7, pp.978-86, 2018. ,
Patterns of Responses in Metastatic NSCLC during PD-1 or PDL-1 Inhibitor Therapy: Comparison of RECIST 1.1, IrRECIST and IRECIST Criteria, European Journal of Cancer, vol.88, pp.38-47, 1990. ,
Therapeutic Efficacy of Ipilimumab, an Anti-CTLA-4 Monoclonal Antibody, in Patients with Metastatic Melanoma Unresponsive to Prior Systemic Treatments: Clinical and Immunological Evidence from Three Patient Cases, Cancer Immunology, Immunotherapy: CII, vol.58, issue.8, pp.1297-1306, 2009. ,
Immunologic and Clinical Effects of Antibody Blockade of Cytotoxic T Lymphocyte-Associated Antigen 4 in Previously Vaccinated Cancer Patients, Proceedings of the National Academy of Sciences of the United States of America, vol.105, pp.3005-3015, 2008. ,
IRECIST: Guidelines for Response Criteria for Use in Trials Testing Immunotherapeutics, The Lancet. Oncology, vol.18, issue.3, pp.143-52, 2017. ,
Prediction of Response to Immune Checkpoint Inhibitor Therapy Using Early-Time-Point 18F-FDG PET/CT Imaging in Patients with Advanced Melanoma, Journal of Nuclear Medicine, vol.58, issue.9, pp.1421-1449, 2017. ,
18F-FDG PET/CT in Non-Small-Cell Lung Cancer Patients: A Potential Predictive Biomarker of Response to Immunotherapy, Nuclear Medicine Communications, 2019. ,
Pretreatment Tumor 18F-FDG Uptake Improves Risk Stratification Beyond RECIST 1.1 in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer: FDG Uptake and Risk Stratification, Clinical Nuclear Medicine, vol.44, issue.2, pp.60-67, 2019. ,
Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.1, pp.56-66, 2018. ,
The Role of Interim 18F-FDG PET/CT in Prediction of Response to Ipilimumab Treatment in Metastatic Melanoma, European Journal of Nuclear Medicine and Molecular Imaging, vol.45, issue.8, pp.1289-96, 2018. ,
Monitoring Anti-PD-1-Based Immunotherapy in Non-Small Cell Lung Cancer with FDG PET: Introduction of IPERCIST, EJNMMI Research, vol.9, issue.1, p.8, 2019. ,
Increased FDG Avidity in Lymphoid Tissue Associated with Response to Combined Immune Checkpoint Blockade, Journal for Immunotherapy of Cancer, vol.4, p.58, 2016. ,
Comparison of RECIST, IRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer, Clinical Nuclear Medicine, 2019. ,
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors, Journal of Nuclear Medicine, vol.50, issue.1, pp.122-150, 2009. ,
A Multifactorial Model of T Cell Expansion and Durable Clinical Benefit In Response to a PD-L1 Inhibitor, PloS One, vol.13, issue.12, p.208422, 2018. ,
Novel Patterns of Response under Immunotherapy, Annals of Oncology: Official Journal of the European Society for Medical Oncology, vol.30, issue.3, pp.385-96, 2019. ,
Emerging Therapies for Non-Small Cell Lung Cancer, Journal of Hematology & Oncology, vol.12, 2019. ,
Immune Checkpoint Inhibitors in Malignancy, Australian Prescriber, vol.42, issue.2, p.62, 2019. ,
Pitfalls in the Radiological Response Assessment of Immunotherapy, vol.11, pp.138-181, 2018. ,
Patterns of Response and Progression to Immunotherapy, Annual Meeting, vol.38, pp.169-78, 2018. ,
Pseudoprogression and Immune-Related Response in Solid Tumors, Journal of Clinical Oncology, vol.33, issue.31, pp.3541-3584, 2015. ,
Symptomatic Pseudo-Progression Followed by Significant Treatment Response in Two Lung Cancer Patients Treated with Immunotherapy, Lung Cancer, vol.113, pp.4-6, 2017. ,
, Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer, Journal of Thoracic Oncology, vol.13, issue.7, pp.978-86, 2018.
Patterns of Response to Anti-PD-1 Treatment: An Exploratory Comparison of Four Radiological Response Criteria and Associations with Overall Survival in Metastatic Melanoma Patients, British Journal of Cancer, vol.115, issue.10, pp.1186-92, 2016. ,
Comparison of RECIST to Immune-Related Response Criteria in Patients with Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors, Cancer Chemotherapy and Pharmacology, vol.80, issue.3, pp.591-98, 2017. ,
Immune-Related Response Assessment during PD-1 Inhibitor Therapy in Advanced Non-Small-Cell Lung Cancer Patients, Journal for Immunotherapy of Cancer, vol.4, p.84, 2016. ,
The Blockade of Immune Checkpoints in Cancer Immunotherapy, Nature Reviews. Cancer, vol.12, issue.4, pp.252-64, 2012. ,
Atypical Responses in Patients with Advanced Melanoma, Lung Cancer, Renal-Cell Carcinoma and Other Solid Tumors Treated with Anti-PD-1 Drugs: A Systematic Review, Cancer Treatment Reviews, vol.59, pp.71-78, 2017. ,
Comparison of RECIST, EORTC Criteria and PERCIST for Evaluation of Early Response to Chemotherapy in Patients with Non-Small-Cell Lung Cancer, European Journal of Nuclear Medicine and Molecular Imaging, vol.43, issue.11, pp.1945-53, 2016. ,
Curative Effect Assessment of Immunotherapy for Non-Small Cell Lung Cancer: The 'Blind Area' of Immune Response Evaluation Criteria in Solid Tumors (IRECIST), Thoracic Cancer, vol.10, issue.4, pp.587-92, 2019. ,
Atypical Response Patterns in Patients Treated With Nivolumab, AJR. American Journal of Roentgenology, pp.1-5, 2019. ,
Immune RECIST Criteria and Symptomatic Pseudoprogression in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy, Radiology and Oncology, vol.52, issue.4, pp.365-69, 2018. ,
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, vol.15, pp.7412-7432, 2009. ,
, Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death, vol.1
ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.33, issue.18, pp.2004-2016, 2015. ,
Pembrolizumab versus Docetaxel for Previously Treated, PD-L1-Positive, Advanced Non-Small-Cell Lung Cancer (KEYNOTE-010): A Randomised Controlled Trial, Lancet, vol.387, pp.1540-50, 2016. ,
,
, Au moment d'être admise à exercer la médecine, je promets et je jure d'être fidèle aux lois de l'honneur et de la probité
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux
, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte
, J'informerai les patients des décisions envisagées, de leurs raisons et de leurs